REGENXBIO Stock Forecast

Stock Price Forecast

According to 11 analysts polled by S&P Global, REGENXBIO stock has a consensus rating of "Buy" and an average price target of $24.36. The average 1-year stock price forecast is 132.44% higher than the current stock price, while the lowest is $10 (-4.58%) and the highest is $50 (+377.10%).

Price Target: $24.36 (+132.44%)

Analyst Consensus: Buy

Target	Low	Average	Median	High
Price	$10	$24.36	$19	$50
Change	-4.58%	+132.44%	+81.30%	+377.10%

Analyst Ratings

The average analyst rating for REGENXBIO stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

Rating	Jan '26	Feb '26	Mar '26	Apr '26	May '26	Jun '26
Strong Buy	6	6	6	6	6	6
Buy	4	4	4	4	4	4
Hold	1	1	1	1	1	1
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	11	11	11	11	11	11

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Annabel Samimy Stifel Nicolaus	Stifel Nicolaus	Buy Reiterates $42	Buy	Reiterates	$42	+300.76%	Jun 25, 2026
Judah Frommer Morgan Stanley	Morgan Stanley	Buy Maintains $16	Buy	Maintains	$16	+52.67%	Jun 25, 2026
Brian Skorney Robert W. Baird	Robert W. Baird	Buy Maintains $27 → $32	Buy	Maintains	$27 → $32	+205.34%	Jun 23, 2026
Yi Chen H.C. Wainwright	H.C. Wainwright	Buy Reiterates $30 → $26	Buy	Reiterates	$30 → $26	+148.09%	Jun 22, 2026
Mani Foroohar Leerink Partners	Leerink Partners	Buy Maintains $18 → $17	Buy	Maintains	$18 → $17	+62.21%	May 15, 2026

More Analyst Ratings

Financial Forecast

Revenue This Year

237.89M

from 170.44M

39.57%

from 170.44M

Revenue Next Year

247.51M

from 237.89M

4.05%

from 237.89M

EPS This Year

-2.82

from -3.76

EPS Next Year

-2.57

from -2.82

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	470.35M	112.72M	90.24M	83.33M	170.44M	237.89M
Revenue Growth	204.30%	-76.03%	-19.94%	-7.66%	104.54%	39.57%
Gross Profit	237.08M	-184.27M	-176.24M	-158.76M	-78.16M	220.05M
Gross Margin	50.40%	-163.47%	-195.29%	-190.53%	-45.86%	92.50%
Operating Income	159.98M	-255.38M	-264.43M	-231.25M	-161.20M	-171.40M
Net Income	127.84M	-280.32M	-263.49M	-227.10M	-193.88M	-173.72M
EPS	-	-	-	-	-3.76	-2.82
Free Cash Flow	72.51M	-156.11M	-133.51M	-95.45M	-79.79M	-146.40M
No. Analysts	-	-	-	-	-	10

EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue	2026	2027	2028
High	389.0M
Avg	237.9M
Low	135.0M

Revenue Growth

Revenue Growth	2026	2027	2028
High	128.2%
Avg	39.6%
Low	-20.8%

EPS Forecast

EPS	2026	2027	2028
High	1.61
Avg	-2.82
Low	-4.91

EPS Growth

EPS Growth	2026	2027	2028
High	-
Avg	-
Low	-